China Preeclampsia Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
China · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$105.7 MnPlaceholder estimate
Estimate 2025$114.6 Mn7.1% of the global market
Projected 2034$236.8 Mn 106.7%Adds $122.2 Mn over 9 forecast years
CAGR 2025–20348.4%Faster than 26% of 173 Medical Devices markets here
Key players5
China is 7.15% of the global market.
In APAC, the largest is China (this report) at $114.6 Mn.
7 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The China Preeclampsia Diagnostics Market Analysis Executive Summary
Preeclampsia diagnostics are blood tests and monitoring tools that predict or detect dangerous high blood pressure in pregnancy.
Key segments of the preeclampsia Diagnostics market include test (sFlt-1/PlGF Ratio Tests, PlGF Tests and Blood Pressure Monitoring) and use (Screening, Diagnosis and Prognosis).
China Preeclampsia Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
China Preeclampsia Diagnostics Market Dynamics
Market Growth Drivers
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.
Opportunity
Femtech, personalised care and new treatments for under-served conditions open strong growth for the preeclampsia Diagnostics market, especially as employers and payers add women's health benefits.
Market Restraints
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the preeclampsia Diagnostics market.
Competitive Landscape for Preeclampsia Diagnostics Market in China
The preeclampsia Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Preeclampsia Diagnostics Market in China
Preeclampsia Diagnostics in China: rules, payment and research
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.[2] ClinicalTrials.gov lists 7 studies on Preeclampsia Diagnostics that are recruiting, active or about to start in China.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how preeclampsia Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Use
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Roche Diagnostics
7.2 Thermo Fisher Scientific
7.3 PerkinElmer (Revvity)
7.4 Siemens Healthineers
7.5 QuidelOrtho
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The preeclampsia Diagnostics market can be segmented based on various criteria, including test, use and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Preeclampsia Diagnostics in context
China compared
Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
How big is the Preeclampsia Diagnostics market in China?
Placeholder estimate: about $114.6 Mn in 2025, rising to about $236.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Preeclampsia Diagnostics market in China growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Preeclampsia Diagnostics market report cover?
The report splits the market by test (sFlt-1/PlGF Ratio Tests, PlGF Tests, Blood Pressure Monitoring, Urine Protein Tests), use (Screening, Diagnosis, Prognosis) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Preeclampsia Diagnostics market?
Key players include Roche Diagnostics, Thermo Fisher Scientific Inc., Perkin Elmer, Siemens Healthineers and Quidel Corporation.
What is driving the Preeclampsia Diagnostics market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.
Who regulates Preeclampsia Diagnostics in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Preeclampsia Diagnostics are running in China?
7 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Preeclampsia Diagnostics?
PubMed lists 7,556 papers on Preeclampsia Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.